Eritoran: The evidence of its therapeutic potential in sepsis

Core Evidence

Volumn 2, Issue 3, 2008, Pages 199-207

  Raja, Shahzad G ^a   Dreyfus, Gilles D ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Eritoran; Evidence; Outcome; Sepsis; Systemic inflammatory response syndrome; Toll like receptor

Indexed keywords

ANTIINFECTIVE AGENT; DROTRECOGIN; ERITORAN; FLUDROCORTISONE; HYDROCORTISONE; INSULIN; PLACEBO; SOMATOMEDIN C; STEROID; TOLL LIKE RECEPTOR 4;

ACUTE LUNG INJURY; ANTICOAGULATION; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; ENDOTOXEMIA; ERADICATION THERAPY; EVIDENCE BASED PRACTICE; FLUID THERAPY; GLYCEMIC CONTROL; HEMODYNAMIC MONITORING; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; LOW DRUG DOSE; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHLEBITIS; POSITIVE END EXPIRATORY PRESSURE; REVIEW; RHINITIS; RISK REDUCTION; SEPSIS; SEPTIC SHOCK; SINGLE DRUG DOSE; THERAPY DELAY;

EID: 65849141281     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Aird WC. Endothelium as a therapeutic target in sepsis. Curr Drug Targets. 2007;8:501-507.
2. Amato MB, Barbas CS, Medeiros DM, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med. 1998;338:347-354.
3. Angus DC, Wax RS. Epidemiology of sepsis: An update. Crit Care Med. 2001;29(Suppl. 1):S109-S116.
4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-1310.
5. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862-871.
6. Anon. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N Engl J Med. 1987;317:659-665.
7. Anon. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342:1301-1308.
8. Anon. Eritoran [E 5564] reduces 28-day mortality in patients with severe sepsis. Inpharma Weekly. 2005;1:8.
9. Bennett-Guerrero E, Grocott HP, Levy JH, et al. A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth Analg. 2007;104:378-383.
10. Bernard GR, Vincent J, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
11. Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998;26:645-650.
12. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-658.
13. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study. Crit Care Med. 1999;27:723-732.
14. Cavaillon JM, Annane D. Compartmentalization of the inflammatory response in sepsis and SIRS. J Endotoxin Res. 2006;12:151-170
15. Cinel I, Dellinger RP. Current treatment of severe sepsis. Curr Infect Dis Rep. 2006;8:358-365.
16. Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420:885-891.
17. Czeslick E, Struppert A, Simm A, Sablotzki A. E5564 (Eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes. Inflamm Res. 2006;55:511-515.
18. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858-873.
19. Dremsizov TT, Kellum JA, Angus DC. Incidence and definition of sepsis and associated organ dysfunction. Int J Artif Organs. 2004;27:352-359.
20. Edbrooke DL, Hibbert CL, Kingsley JM, Smith S, Bright NM, Quinn JM. The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit Care Med. 1999;27:1760-1767.
21. Eisai Inc. Eisai announce phase II results, plans to initiate phase III clinical trial program for eritoran as a treatment for severe sepsis. Ridgefield Park, NJ: Eisai Inc. press release; August 2005. Available at: http://www.eisai.com/view_press_release.asp?ID=210&press= 124 (accessed July 1, 2007).
22. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med. 2001;29(Suppl.):S48-S51.
23. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med. 2004;30:589-596.
24. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 1992;101:816-823.
25. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med. 1995;333:1025-1032.
26. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med. 1994;330:1717-1722.
27. Heyland DK, Hopman W, Coo H, Tranmer J, McColl MA. Long-term health-related quality of life in survivors of sepsis. Short Form 36: A valid and reliable measure of health-related quality of life. Crit Care Med. 2000;28:3599-3605.
28. IHI (Institute for Healthcare Improvements). Surviving Sepsis Campaign. Sepsis. Available at: http://www.ihi.org/IHI/Topics/ CriticalCare/Sepsis/Changes/ (accessed June 28, 2007).
29. Jean-Baptiste E. Cellular mechanisms in sepsis. J Intensive Care Med. 2007;22:63-72.
30. Kleinpell RM, Graves BT, Ackerman MH. Incidence, pathogenesis, and management of sepsis: An overview. AACN Adv Crit Care. 2006;17:385-393.
31. Korosec Jagodic H, Jagodic K, Podbregar M. Long-term outcome and quality of life of patients treated in surgical intensive care: A comparison between sepsis and trauma. Crit Care. 2006;10:R134.
32. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589-1596.
33. Liang E, Wong YN, Allen I, Kao R, Marino M, DiLea C. Pharmacokinetics of E5564, a lipopolysaccharide antagonist, in patients with impaired hepatic function. J Clin Pharmacol. 2003;43:1361-1369.
34. Linde-Zwirble WT, Angus DC. Severe sepsis epidemiology: Sampling, selection, and society. Crit Care. 2004;8:222-226.
35. Lynn M, Rossignol DP, Wheeler JL, et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis. 2003;187:631-639.
36. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546-1554.
37. Mullarkey M, Rose JR, Bristol J, et al. Inhibition of endotoxin response by E5564, a novel toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther. 2003;304:1093-1102.
38. Nguyen HB, Smith D. Sepsis in the 21st century: Recent definitions and therapeutic advances. Am J Emerg Med. 2007;25:564-571.
39. Nilsson L, Kulander L, Nystrom SO, Eriksson O. Endotoxins in cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1990;100:777-780.
40. Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med. 2003;31:2332-2338.
41. Poulton B. Advances in the management of sepsis: The randomized controlled trials behind the Surviving Sepsis Campaign recommendations. Int J Antimicrob Agents. 2006;27:97-101.
42. Remick DG. Pathophysiology of sepsis. Am J Pathol. 2007;170:1435-1444.
43. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-1377.
44. Rocke DA, Gaffin SL, Wells MT, et al. Endotoxemia associated with cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1987;93:832-837.
45. Rossignol DP, Wasan KM, Choo E, et al. Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Antimicrob Agents Chemother. 2004;48:3233-3240.
46. Sessler CN. Steroids for septic shock: Back from the dead? (Con). Chest. 2003;123(Suppl.):482S-489S.
47. Trinchieri G, Sher A. Cooperation of toll-like receptor signals in innate immune defence. Nat Rev Immunol. 2007;7:179-190.
48. Tsiotou AG, Sakorafas GH, Anagnostopoulos G, Bramis J. Septic shock; current pathogenetic concepts from a clinical perspective. Med Sci Monit. 2005;11:RA76-RA85.
49. Uematsu S, Akira S. Toll-like receptors and innate immunity. J Mol Med. 2006;84:712-725.
50. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359-1367.
51. Verstak B, Hertzog P, Mansell A. Toll-like receptor signalling and the clinical benefits that lie within. Inflamm Res. 2007;56:1-10